Defining the Starting Dose
暂无分享,去创建一个
[1] J. Verweij,et al. Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Groshen,et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. , 2002, Journal of the National Cancer Institute.
[3] Brigitte Tranchand,et al. Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. , 2002, British journal of clinical pharmacology.
[4] H. Gurney,et al. How to calculate the dose of chemotherapy , 2002, British Journal of Cancer.
[5] H. Groen,et al. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene , 2002, British Journal of Cancer.
[6] Hideyuki Saito,et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. , 2002, Journal of the American Society of Nephrology : JASN.
[7] C. Klaassen,et al. Induction of rat organic anion transporting polypeptide 2 by pregnenolone-16alpha-carbonitrile is via interaction with pregnane X receptor. , 2002, Molecular pharmacology.
[8] Paul T Tarr,et al. Regulation of Multidrug Resistance-associated Protein 2 (ABCC2) by the Nuclear Receptors Pregnane X Receptor, Farnesoid X-activated Receptor, and Constitutive Androstane Receptor* , 2002, The Journal of Biological Chemistry.
[9] D. V. Von Hoff,et al. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] J. Hudson,et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. , 2001, Pharmacogenetics.
[11] J. Verweij,et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Kigawa,et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. , 2001, The Journal of pharmacology and experimental therapeutics.
[13] Ann Daly,et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.
[14] L Landmann,et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. , 2001, Gastroenterology.
[15] S. Poole,et al. Poor correlation between body surface area and glomerular filtration rate , 2000, Cancer Chemotherapy and Pharmacology.
[16] A. Cranendonk,et al. Clinical pharmacokinetics of phenobarbital in neonates. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[17] S. Chan,et al. Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. , 2000, British journal of clinical pharmacology.
[18] J. Bergh,et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial , 2000, The Lancet.
[19] Sudhakar M. Pai,et al. Population Pharmacokinetics of Temozolomide in Cancer Patients , 2000, Pharmaceutical Research.
[20] P. Beale,et al. Optimizing the erythromycin breath test for use in cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] D. Xuan,et al. Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen. , 2000, International journal of antimicrobial agents.
[22] J. Verweij,et al. Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] J. Beijnen,et al. The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[24] G. Weiss,et al. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Robert,et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Sockrider,et al. Pharmacokinetics of Ibuprofen in Patients with Cystic Fibrosis , 1999, Pharmacotherapy.
[27] Kyoichi Ohashi,et al. Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer , 1998, Annals of Internal Medicine.
[28] P. Angus,et al. Relationships among liver and kidney volumes, lean body mass and drug clearance. , 1998, British journal of clinical pharmacology.
[29] N. Dobbs,et al. What is the effect of adjusting epirubicin doses for body surface area? , 1998, British Journal of Cancer.
[30] M. Czuczman,et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] V. Gebski,et al. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] M. Ratain. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] T. Yasuzawa,et al. Identification of novel metabolites of vinorelbine in rat. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.
[34] L. Nguyen,et al. Population pharmacokinetics of total and unbound etoposide , 1997, Cancer Chemotherapy and Pharmacology.
[35] B. Ring,et al. The human drug metabolizing cytochromes P450 , 1996, Journal of Pharmacokinetics and Biopharmaceutics.
[36] H. Gurney,et al. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Lewis B. Sheiner,et al. A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation , 1996, Journal of Pharmacokinetics and Biopharmaceutics.
[38] H. Rosing,et al. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[39] O. Dassonville,et al. [Population study of dihydropyrimidine dehydrogenase in cancer patients]. , 1994, Bulletin du cancer.
[40] D. Morgan,et al. Lean Body Mass as a Predictor of Drug Dosage , 1994, Clinical pharmacokinetics.
[41] P. Workman,et al. Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? , 1993, Cancer Chemotherapy and Pharmacology.
[42] G Cheymol,et al. Clinical Pharmacokinetics of Drugs in Obesity , 1993, Clinical pharmacokinetics.
[43] A. van der Gaast,et al. What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 x 100 mg, 2 x 50 mg, and 4 x 25 mg of oral etoposide daily for 21 days. , 1992, Seminars in oncology.
[44] R. Motzer,et al. Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience. , 1992, Seminars in oncology.
[45] C. Hunt,et al. Effect of age and gender on the activity of human hepatic CYP3A. , 1992, Biochemical pharmacology.
[46] J. Rodman,et al. The pharmacokinetics of high‐dose carboplatin in pediatric patients with cancer , 1992, Clinical pharmacology and therapeutics.
[47] C. Stewart,et al. Disposition of high‐dose methotrexate in an obese cancer patient , 1991, Cancer.
[48] M. Green,et al. Pharmacokinetics and toxicity of two schedules of high dose epirubicin. , 1990, Cancer research.
[49] L. Grochow,et al. Is dose normalization to weight or body surface area useful in adults? , 1990, Journal of the National Cancer Institute.
[50] E Wiltshaw,et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] D. DuBois,et al. A formula to estimate the approximate surface area if height and weight be known , 1989 .
[52] D. Rushing,et al. Doxorubicin clearance in the obese. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] M Slavik,et al. Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. , 1975, Cancer research.
[54] E J Freireich,et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. , 1966, Cancer chemotherapy reports.
[55] D. Pinkel. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. , 1958, Cancer research.
[56] Homer W. Smith. The Kidney: Structure and Function in Health and Disease , 1952 .
[57] J. Crawford,et al. Simplification of drug dosage calculation by application of the surface area principle. , 1950, Pediatrics.
[58] D. D. Bois,et al. CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWN , 1916 .
[59] M. Millward,et al. Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer , 2004, Cancer Chemotherapy and Pharmacology.
[60] P. Wilkinson,et al. Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution , 2004, Cancer Chemotherapy and Pharmacology.
[61] J. Ingle,et al. Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients , 2004, Cancer Chemotherapy and Pharmacology.
[62] K. Itoh,et al. Factors Affecting the Pharmacokinetics of CPT-11: The Body Mass Index, Age and Sex are Independent Predictors of Pharmacokinetic Parameters of CPT-11 , 2004, Investigational New Drugs.
[63] E. Berry,et al. Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism , 2004, European Journal of Clinical Pharmacology.
[64] B. Goodwin,et al. Regulation of hepatic drug metabolism: role of the nuclear receptors PXR and CAR. , 2002, Seminars in liver disease.
[65] J. Verweij,et al. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] R. Schilsky,et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity , 2002, The Pharmacogenomics Journal.
[67] M. Ratain,et al. Pharmacogenetics , 2000, Clinical pharmacokinetics.
[68] N. Mcintyre,et al. Oxford Textbook of Clinical Hepatology , 1999 .
[69] F. Appelbaum,et al. The impact of obesity and disease on busulfan oral clearance in adults. , 1999, Blood.
[70] L B Sheiner,et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] T. Goya,et al. The influence of relative body weight on toxicity of combination chemotherapy with cisplatin and etoposide , 1998, Cancer Chemotherapy and Pharmacology.
[72] G. Bonadonna,et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] Malcolm Rowland,et al. Clinical pharmacokinetics : concepts and applications , 1989 .
[74] M. Schnegg,et al. Quantitative liver function in the elderly assessed by galactose elimination capacity, aminopyrine demethylation and caffeine clearance. , 1986, Journal of hepatology.